



Stock Code **3224**

METATECH (AP) INC. Investor Conference

2025/12/16

Disclaimer


The contents of this presentation and related information are the information collected by the company from various prior documents.

The Company is dedicated to the future development. The actual results of operations, financial condition and business achievement may differ from the forecasted information. This may be due to risk factors that are not expected to be captured by market conditions.

The future development described in this presentation is based on the judgment of market information and the development of the Group's business strategy. The Company is not responsible for alerting or updating for future development as it may be adjusted with the market trend.

Governance Evaluation Score Distribution of OTC Company

Stable Corporate Governance



簡報
大綱

1

**Electronics Division Status and
Future Market Strategy**

2

**Biomedical Division Status and
Technical Development**

3

**Biomedical Digitalization
Strategy**

01.


Electronics Division Status and Future Market Strategy

AI Market Applications and
Strategic Goals




Revenue

Unit: NT\$ Thousands



Performance


Unit: NT\$ Thousands



AI Server Applications

AI Server Market

Size, by Processor Type, 2020~2030(USD Billion)



The Company continues to deploy in the Artificial Intelligence (AI) server field. Our products are primarily applied to the high-speed transmission and connection requirements of AI servers, covering two major categories: **high-frequency connectors and high-frequency cables**.

As the demand for AI computing grows rapidly, the demand for high-speed transmission interfaces increases synchronously. The Company's shipment volume for related products is steadily increasing.

We are actively seeking upstream and downstream partners in this market to align with market trends.




AI Power Supply Applications

Power Supply Units (PSU) Market

Market Size in USD Billion

Market Growth and Scale



The Power Supply Unit market size is estimated to be USD 35.86 billion in 2025 and is expected to reach USD 49.29 billion by 2030, with a Compound Annual Growth Rate (CAGR) of 6.57% during the forecast period (2025-2030).


Study Period	2019~2030
Market Size (2025)	USD 35.86 Billion
Market Size (2030)	USD 49.29 Billion
CAGR (2025-2030)	6.57%
Fastest Growing Market	Asia Pacific
Largest Market	Asia Pacific
Market Concentration	Medium

Market Players



The Company continues to deploy in the AI power supply market. Our agency products primarily target **High Voltage and High Current** applications, covering connectors and cables.

As power demands for AI servers and data centers continue to rise, the importance of high-power transmission solutions is increasing daily. We continuously seek product line agencies in this application field to enhance reliability and safety, ensuring stable operation under high-load environments, thereby further strengthening the Company's competitiveness in the AI power application sector.




Source: Global Information, Inc. (GII)

Website: <https://www.gii.tw/report/moi1692532-power-supply-units-psu-market-share-analysis.html>

Co-Packaged Optics(CPO) Market Size 2025 to 2034 (USD Million)

Market Growth and Scale




In the semiconductor market, the Company's products are mainly applied in **CPC (Co-Packaged Copper) and CPO (Co-Packaged Optics)** architectures for high-speed transmission solutions.

Targeting these two emerging architectures, we are identifying potential customers and assisting upstream partners in promoting **high-performance connectors and high-frequency cables** to meet the needs for high-speed data transmission and low latency.


As CPC and CPO technologies are gradually introduced into advanced packaging and AI computing fields, the demand for related products is expected to continue growing, driving the Company's development momentum in the semiconductor application market.



Revenue Share by Market Segment



Estimated Revenue Share Growth for 2026



02.

**Biomedical Division Status
and Technical Development**




Biomedical Division Revenue Continues Significant Growth

MetaTech partners with Hannah Quinlivan to promote the future of health, welcoming the launch of Taiwan's 'Dual Regenerative Medicine Laws' and leading the new trend of family iPSC banking



Source: 2025.11.06 Sun Media Report




2023-2025

Two-Year Growth Rate **↑ 307%**

Number of Partner Institutions Continues to Grow



Partner Clinics **71** Clinics
(Covering northern, central, and southern regions)



- **Cell Authentication Clinics:** **7+4** Clinics
- **Regulations of Special Medical Techniques approved Institutions:** **12** Clinics
- **iPSC Partner Clinics:** **55** Clinics

Taiwan's Regenerative Medicine Act — Launching a New Era of Cell Therapy

2026: Regenerative Medicine Act officially launches, injecting new momentum into the cell therapy industry.

- Regenerative Medicinal Products Act: Strengthening GMP standards to ensure safety and consistency of cell preparations.
- MetaTech is the first cell preparation factory in Taiwan to obtain PIC/S GMP certification (the 25th in Asia), promoting international technology implementation and industrial upgrading.




Amendment Item	Original Legislation	Act on Regenerative Medicine Treatments	Act on Regenerative Medicinal Products	<Sub-method project>	MetaTech Group Advantages
1. Legal Compliance	Fragmented regulation, poor implementation	Act on Regenerative Medicine Treatments: Regulations on medical technology and therapeutic institutions	Act on Regenerative Medicinal Products: Regulations on the production and application of therapeutic products	1. Regenerative Medicine Review Board	<ul style="list-style-type: none"> • Extensive experience in cell therapy and strong familiarity with regulatory review processes. • Dedicated Clinical/CMC/Regulatory teams.
2. Scope of Therapy	Undefined, narrow coverage	Includes genetic modification, stem cells, and derivatives (Article 3)		2. R&D Incentives	<ul style="list-style-type: none"> • Multi-track R&D in autologous/allogeneic cells, iPSC, exosomes. • Proprietary technology and patent layout.
3. Quality and Safety	No product-specific production regulations	Requires professional technical review and safety evaluation (Article 14)	Compliance with GMP and GDP standards (Article 16)	3. Tech & Preparation Management	<ul style="list-style-type: none"> • Taiwan's first PIC/S GMP cell preparation factory. • Contracted cooperation with multiple medical institutions.
4. Human Trials	Trials require completion of all phases	Specific circumstances allow partial trial exemptions (Article 7 and 8)	Completion of Phase II clinical trials allows for conditional application for licensure (Articles 6–9)	4. Informed Consent	<ul style="list-style-type: none"> • Compliant with donor informed consent and risk control.
5. Strengthened Execution	Inconsistent management and regulatory framework	Non-medical institutions are prohibited from performing regenerative medicine (Article 11)	Management of product suitability and traceability (Articles 11, 12, and 18)	5. Advertising Management	<ul style="list-style-type: none"> • Compliant publication.

MetaTech Leverages Dual Regenerative Medicine Laws to Showcase Core Competence




Regenerative Medicine Laws: Legal Highlights	Regenerative Medicine Act	Regenerative Medicine Production Regulations	MetaTech Group Advantages
<p>Cell Operation Regulations and Production Requirements Compliance with GMP and GDP Standards</p>	Article 14	Article 16	<p>Taiwan's First PIC/S GMP Cell Preparation Pilot Plant : Subsidiary Locus Cell operates Asia's largest PIC/S GMP facility, set to launch in 2026.</p>
<p>Medical Institution Standards and Professional Requirements Execution of Regenerative Medicine in Approved Medical Institutions</p>	Article 11 Article 13	Article 17	<p>Leading Industry Layout : Partner clinics increased to 71, comprehensively promoting regenerative medicine applications.</p>
<p>Accelerated Introduction of International Clinical Outcomes Direct integration of results from international Phase II trials</p>	Article 8 Paragraph 1	Article 6 Article 9	<p>International Cooperation & Rapid Market Entry : Signed MOU with Japan's Megakaryon. MetaTech has built an AI "GMP Document Generation" platform in collaboration with Japan's CM Plus, creating a cross-border AI digital advanced medical regulatory ecosystem, acting as mutual agents.</p>
<p>Technical Innovation Support Regenerative medicine R&D is eligible for government incentives or subsidies.</p>	Article 10		<p>Diverse Technology Platform : Integrating AI, digitization, and smart factory concepts to drive personalized regenerative medicine technologies.</p>
<p>Cell Source Management Ensuring the suitability of cell donors through testing and preservation.</p>	Article 17	Article 18	<p>Comprehensive Integration Capability : Providing one-stop services from cell source management to processing, supporting clinical trials and commercial applications. Possesses organoid differentiation technology, serving as both a drug screening platform and seeding the future of cell therapy.</p>

Personalized Precision Medicine—Starting with iPSC (Induced Pluripotent Stem Cells) Banking



- 2024: Build Taiwan's No. 1 Brand for Personalized iPSC Banking.
- 2025: Become Taiwan's Largest Private Biobank.
- 2026: Surpass South Korea's Public Biobank.

Diverse Development of iPSC Banking: A New Plan for the Next Generation of Cell Therapy



METATECH GROUP

iPSC Banking Services

- Personalized Family Health Cell Bank
- Drug Screening Platform
- Seeds for Personalized Precision Cell Therapies:

Established multiple iPSC differentiation technology platforms covering key technologies for Heart, Kidney, and Retinal Ganglion Cells.

Clinical Trial Progress

Cell-Therapy Product	Indication	Phase	2025	2026				2027			
Autologous Oral Epithelial Cells	Esophageal Cancer	III	Clinical Trial Ongoing				Approval Review	Inspection Registration Application			
Allogeneic Stem Cells	Kidney Injury	IND preparation	Complete Preclinical Testing	CDE Consultation	IND Submission	Clinical Trial Ongoing					
Allogeneic Stem Cells	Underactive bladder	IND preparation	Complete Preclinical Testing	CDE Consultation	IND Submission	Clinical Trial Ongoing					

03.

Biomedical Digitalization Strategy

**From Data to Decision: How ICT
and AI Realize the Smart
Upgrade of Regenerative
Medicine Manufacturing**



Upgrade and Transform

Digitization + Automation + Intelligence



Near Term

**Cell Preparation Center (CPC)
AI and Digital Twin**

Cross-Domain Integration

Biotech + ICT + Medical Engineering
Technology



Mid Term

**Integrated, Intelligent
Collaborative Model**

Creating Win-Win

MetaTech Group + Domestic Strategic
Partners + International Strategic Partners



Long Term

**Comprehensive Facility
Intelligence Expansion &
International Cloud Services**



MetaTech has accumulated a vast amount of GMP documentation

6 Years

experience and massive documentation

3

GMP Assessments passed

11


GTP Inspections passed

One cell product line requires over 1,000 GMP documents

NEOKATANA™- AI GMP Document Generation System



BEFORE Multiple personnel across multiple departments required to draft a single document




NEOKATANA-AI GMP Document Generation System

AFTER One person, one computer, one-click document generation (Shortens R&D time, reduces costs)

Benefits of NEOKATANA™

Based on approx. 1,220 quality documents at MetaTech's Xizhi plant



MetaTech & CM Plus Jointly Build Cross-National GMP AI Document Platform

《The Globe and Mail》 reported on the partnership



MetaTech and CM Plus Establish Strategic Partnership to Build "AI Katana" Platform for Biotech Market Expansion in Japan and Asia

GetNews - TGAM - [GetNews](#) - Mon Oct 13, 11:44AM CDT

TOKYO/TAIPEI - October 13, 2025 - MetaTech (AP) Inc. (TWSE: 3224), a leading Taiwanese biotech AI technology company, and CM Plus, a multinational enterprise specializing in high-standard engineering management and regulatory compliance (headquartered in Singapore and Yokohama, Japan), have signed a Memorandum of Understanding (MOU) to jointly build a new cross-border platform for accelerating biotech product market entry between Taiwan and Japan.

MetaTech combines with CM Plus to transform physical experience into digital intelligence, jointly developing a next-generation GMP Factory AI System and acting as mutual agents :

- Hard (Hardware Strength)** Specializing in facility engineering design and construction management
- Soft (Software Strength)** Familiar with GMP/QMS regulatory consulting and validation
- Expert (Expert Brain)** Possessing a top-tier team of professional GMP consultants.

工商時報

Taiwan-Japan Major Collaboration: MetaTech and CM Plus Sign MOU to Jointly Build 'AI Katana' Biotech Platform

2025.10.10 / 15:02 / 工商時報 杜蕙蓉



三顧與CM Plus簽署MOU。圖 / 業者提供




Total Patent Applications **36** cases

(30 invention patents, 6 utility patents)

- Invention Patents **30** cases
- Utility Patents **6** cases
- Approved Patents **10** cases

Statistics cutoff date:
December 9, 2025



Taiwan Regenerative Medicine Act — Launching a New Era of Cell Therapy

AI + Regenerative Medicine



**PIC/S GMP Cell
Preparation Pilot Plant
Certification**



**Cell Storage:
The "Seeds" of Cell Therapy**

**Metatech Is Ready To Embrace The Generation Of Personalized Precision
Regenerative Medicine**



MetaTech

三顧股份有限公司

THANK YOU

**Listening Your Feedback is
Highly Appreciated**

Stock Code **3224**